 | |
| Clinical data | |
|---|---|
| Other names | [N-propargyl-(3R)-aminoindan-5yl]-N-propylcarbamate |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C16H20N2O2 |
| Molar mass | 272.348 g·mol−1 |
Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease.[1] It acts as a reversible acetylcholinesterase and butyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.[2][3] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.[4] Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.[5][6]
See also
References
- ^ Weinstock M, Bejar C, Wang RH, et al. (2000). "TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease". Advances in Research on Neurodegeneration. pp. 157–69. doi:10.1007/978-3-7091-6301-6_10. ISBN 978-3-211-83537-1. PMID 11205137.
{{cite book}}:|journal=ignored (help) - ^ Weinreb O, Mandel S, Bar-Am O, et al. (January 2009). "Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs". Neurotherapeutics. 6 (1): 163–74. doi:10.1016/j.nurt.2008.10.030. PMC 5084264. PMID 19110207.
- ^ Weinstock M, Luques L, Bejar C, Shoham S (2006). "Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression". Parkinson's Disease and Related Disorders. pp. 443–6. doi:10.1007/978-3-211-45295-0_67. ISBN 978-3-211-28927-3. PMID 17017566.
{{cite book}}:|journal=ignored (help) - ^ Weinreb O, Amit T, Bar-Am O, Youdim MB (December 2007). "Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy". Annals of the New York Academy of Sciences. 1122 (1): 155–68. Bibcode:2007NYASA1122..155W. doi:10.1196/annals.1403.011. PMID 18077571. S2CID 39753711.
- ^ Weinstock M, Poltyrev T, Bejar C, Youdim MB (March 2002). "Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression". Psychopharmacology. 160 (3): 318–24. doi:10.1007/s00213-001-0978-x. PMID 11889501. S2CID 26001621.
- ^ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (June 2003). "A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease". Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555–61. doi:10.1016/S0278-5846(03)00053-8. PMID 12787840. S2CID 21612561.
This page was last edited on 6 January 2024, at 07:18